Where Orchestra BioMed Hldgs Stands With Analysts

Throughout the last three months, 4 analysts have evaluated Orchestra BioMed Hldgs OBIO, offering a diverse set of opinions from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Orchestra BioMed Hldgs, revealing an average target of $14.5, a high estimate of $20.00, and a low estimate of $12.00. Experiencing a 9.38% decline, the current average is now lower than the previous average price target of $16.00.

Analyzing Analyst Ratings: A Detailed Breakdown

The analysis of recent analyst actions sheds light on the perception of Orchestra BioMed Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Orchestra BioMed Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Orchestra BioMed Hldgs compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Orchestra BioMed Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Orchestra BioMed Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Orchestra BioMed Hldgs analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind Orchestra BioMed Hldgs

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

A Deep Dive into Orchestra BioMed Hldgs's Financials

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Decline in Revenue: Over the 3 months period, Orchestra BioMed Hldgs faced challenges, resulting in a decline of approximately -3.44% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Orchestra BioMed Hldgs's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -6385.38%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Orchestra BioMed Hldgs's ROE excels beyond industry benchmarks, reaching -40.81%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Orchestra BioMed Hldgs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -21.33%, the company may face hurdles in achieving optimal financial returns.

Debt Management: With a below-average debt-to-equity ratio of 0.5, Orchestra BioMed Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst Ratings: Simplified

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.